- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Alzheimer's Disease
Volume 2012 (2012), Article ID 251426, 13 pages
Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease
Experimental Genetics Group (LEGTEGG), Department of Human Genetics, KU Leuven, Campus Gasthuisberg ON1-06.602, Herestraat 49, 3000 Leuven, Belgium
Received 14 February 2012; Accepted 16 March 2012
Academic Editor: Rakez Kayed
Copyright © 2012 Natalia Crespo-Biel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The microtubule-associated protein Tau (MAPT) is a major component of the pathogenesis of a wide variety of brain-damaging disorders, known as tauopathies. These include Alzheimer's disease (AD), denoted as secondary tauopathy because of the obligatory combination with amyloid pathology. In all tauopathies, protein Tau becomes aberrantly phosphorylated, adopts abnormal conformations, and aggregates into fibrils that eventually accumulate as threads in neuropil and as tangles in soma. The argyrophilic neurofibrillary threads and tangles, together denoted as NFT, provide the postmortem pathological diagnosis for all tauopathies. In AD, neurofibrillary threads and tangles (NFTs) are codiagnostic with amyloid depositions but their separated and combined contributions to clinical symptoms remain elusive. Importantly, NFTs are now considered a late event and not directly responsible for early synaptic dysfunctions. Conversely, the biochemical and pathological timeline is not exactly known in human tauopathy, but experimental models point to smaller Tau-aggregates, termed oligomers or multimers, as synaptotoxic in early stages. The challenge is to molecularly define these Tau-isoforms that cause early cognitive and synaptic impairments. Here, we discuss relevant studies and data obtained in our mono- and bigenic validated preclinical models, with the perspective of Tau as a therapeutic target.
It is no coincidence to begin this paper on protein Tau and tauopathies by referring to Alzheimer’s disease (AD), because it is the most frequent tauopathy, albeit a “secondary” one. More than hundred years after the first documented case of AD, the etiology of sporadic forms remains hitherto unknown. Demographic changes, increased life expectancy with a fast growing elderly population, lead us and all future generations to the dramatic increase in the incidence and prevalence of AD—described by some as “the pandemic of the 21st century” .
The extracellular amyloid deposits, c.q. neuritic plaques and cerebrovascular angiopathy, together with the intracellular neurofibrillary threads and tangles (NFT) remain the key pathological markers in AD brain. Nevertheless, the essential basis of cognitive impairment is generally accepted to be reduced synaptic plasticity, evolving into loss of synapses and eventually loss of neurons only in later stages [2–5]. Extensive genetic and biochemical data have implicated the amyloid peptides, the main components of the amyloid deposits, as the central mediators of AD. The amyloid cascade hypothesis, prevailing for more than two decades, stated that the amyloid deposition is the initiating event of neuronal dysfunction and cell death in brain . In familial AD-cases, production of more and longer amyloid peptides, for example, Aβ1–42, by abnormal proteolysis of the membrane-bound amyloid precursor protein (APP) triggers a pathologic cascade, years, or decades before the overt clinical manifestations of the disorder [7–9]. By extension, a similar pathogenic pattern is proposed in sporadic AD cases, whereby increased levels of similar or other amyloid peptides, for example, Aβ1–38, Aβ1–43, pE3Aβ3-x among others, can stem from deviating proteolysis, increased production, failing degradation, and ApoE-mediated elimination from the brain.
The major—if not only—arguments that support the amyloid hypothesis are genetic by nature . The detection of different mutations in the gene coding for APP, but even more so in the gene coding for presenilin-1 (PS1) is defined as causing early onset familial AD . Conversely, overproduction of amyloid peptides from mutant APP, alone or in combination with mutant PS1 in transgenic mouse brain, failed to cause appreciable tauopathy or neuronal degeneration. The question arose whether accumulating amyloid peptides are indeed the real culprit for neurodegeneration in AD. Recent neuroimaging studies demonstrated considerable amyloid deposits in the brain of a sizeable fraction, that is, 15–30% depending on the study, of cognitively normal individuals, whereas clinically diagnosed AD patients can show no amyloid deposition by PET scan [13, 14]. These and other observations have led to the modified amyloid hypothesis, stating that not deposits but soluble toxic amyloid species must initiate AD-pathology, and moreover, that tauopathy is essentially implicated .
For decades, the microtubule-associated protein Tau was known as the main component of NFT, and although occupying the number two spot on the list of proteins implicated in AD, the focus of the field is traditionally aimed on amyloid. Long-standing observations, nevertheless, indicate that neuronal tauopathy provides the closest pathological approximation of clinical defects observed during the life of AD patients. The typical brain-regional occurrence and progression of Tau pathology correlates temporally and spatially well with neuronal and cognitive dysfunction [16, 17], with the added weight of the correlation to CSF-levels of phosphorylated Tau . Therefore, the crucial question remains where protein Tau should be placed in the amyloid cascade hypothesis: downstream, at the same level or even upstream of amyloid? Should we consider protein Tau as a by-stander of the amyloid toxicity, as a mediator or even as a prime player, and therefore preferred target? Only recently fundamental scientist have gained more insight into how these two main defects and players could be linked mechanistically.
Important is that even in young familial AD-cases, amyloid pathology is always accompanied by Tau pathology, similar to late sporadic cases of AD. This establishes tauopathy even more firmly as cause, besides or rather than codiagnostic hallmark in all AD cases! Scientific reasoning takes this one step further, to implicate tauopathy in the more early stages of AD, conform to the origin of pathology in primary tauopathies. Important caveat here is that the early stages of Tau pathology are yet to be defined molecularly in human patients. This was and remains a formidable scientific challenge: biochemical and biophysical definition of the neurotoxic Tau species, which we have termed Tau-P* .
2. Protein Tau: Physiology and Pathology, an Unstable Balance
In contrast to the apparent redundancy of the physiological function of protein Tau, as demonstrated in Tau-deficient mice , the presumed pathological importance of protein Tau was established by the discovery of inherited mutations in the MAPT gene. These are tightly linked to the disease in families suffering autosomal dominant frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [21–24]. Once more, genetic findings established a key factor in the pathogenesis of a disease, in this case protein Tau in a subgroup of FTD, a heterogeneous group of tauopathies characterized by dementia and movement disorders.
The structure of the Tau gene has been reviewed in detail elsewhere [25, 26]. Alternative mRNA splicing of exon 10, encoding the second of four microtubule-binding domains (MTBD) produces two major isoforms, denoted as Tau.3R and Tau.4R, respectively, with lower and higher affinity for microtubules (MT) [27–29]. The abundance of Tau.3R and Tau.4R in human brain changes during brain development and neuronal differentiation. In embryonic brain, Tau.3R isoforms dominate, apparently providing structural and morphological plasticity to developing and differentiating neurons. In mature neurons, Tau.4R gains importance and becomes largely located in axons, excluded from soma and dendrites where other MAPs predominate. In the adult human brain, Tau.3R and Tau.4R isoforms are balanced, while in adult mouse brain the Tau.4R isoforms prevail [30, 31].
Importantly, both intronic and exonic mutations in the MAPT gene are associated with FTDP-17. Many are located in exon 10 or in the surrounding introns, affecting the alternative splicing of this exon. Evidently, intronic mutations produce normal, wild-type proteins, which in case of protein Tau result in the distortion of the normal isoform-balance. An abnormal Tau.3R/4R balance, either increased or decreased, is thought to disturb the function of Tau in MT assembly, stabilization, and transport. Expressed mutations then are presumed to provoke similar problems, while mutant Tau in general is more prone to phosphorylation and polymerization [27–29].
Immunohistochemical and biochemical studies, supported by genetic data, have revealed that in specified tauopathies the pathology directly reflects the aberrant Tau isoform ratio. For instance, in PSP, CBD, and AGD, the inclusions contain mainly Tau.4R isoforms [30, 32, 33], whereas Pick bodies contain mostly Tau.3R. Furthermore, in familial FTD, exonic mutations, for example, P301L, P301S, G272V, N279K, V337M, R406, cause significant overrepresentation of Tau4R [34, 35]. In AD and other tauopathies, variable ad-mixtures of the two major Tau isoforms are biochemically detected in aggregates and deposits in soma, dendrites, and axons. Obviously, an inconsistent picture emerges of Tau isoforms biochemically associated with different tauopathies, although all are pathologically defined by argyrophilic tauopathy.
Our eventual molecular understanding of the role played by abnormal structural features of protein Tau in human tauopathies must ultimately be based on the knowledge of its normal cellular functions. The major, and as far as we know, only physiological function of protein Tau involves its capacity to bind to microtubules to control or affect spacing, stabilization and dynamics [36–38]. That protein Tau is involved in signal transduction, neuronal differentiation, organello-genesis and growth can likely be reduced to the same primary act of MT-binding [39–41]. We will not indulge in describing the processes in which protein Tau has been implicated or proposed, a subject reviewed recently elsewhere .
The function of Tau in adult—and ageing—brain is supposed to be fine-tuned by post-translational mechanisms besides the alternative mRNA splicing producing Tau.3R and Tau.4R isoforms. The prime one is phosphorylation of a limited set of serine and threonine residues, selected among the 79 available. With respect to the mechanism governing this selection, one must not only consider the specificity of different kinases responsible, but also the naturally unfolded nature of protein tau, which presumably exposes most, if not all the S/T residues.
3. Phosphorylation, Missorting, and Aggregation: In What Order and Extent?
Over the last years, following and thanks to the genetic discoveries in the MAPT gene, striking observations in patients but mainly in experimental models have changed some long-established convictions concerning the role of protein Tau in cognitive disorders and neurodegeneration.
In transgenic mice, regulated expression and suppression of mutant protein Tau correlated with defective and improved cognition . Moreover, protein Tau but not NFT appeared involved in neuronal death in transgenic mice and AD patients [44, 45]. Elimination of protein Tau in an amyloid mouse model restored cognitive and behavioral deficits , corroborating observations in AD patients that tauopathy defines the cognitive demise, discussed above. Moreover, not APP but protein Tau proved neurotoxic for pyramidal neurons in CA1 and cortex in a nontransgenic, AAV-based model, with formation of oligomeric but not fibrillar Tau .
Ideas that have been simmering for years are more and more substantiating that specified neuronal dysfunctions are evident before NFTs are deposited. Moreover, the synapto- and neurotoxicity of protein Tau depends on its posttranslational modifications, in first instance O-phosphorylation, but also others that need to be explored in detail: Y-phosphorylation, glycation, glycosylation, acetylation, sumoylation, among others [48–52]. Therefore, accurate temporal and spatial patterns of pathological traits that must also be physiologically important deserve investigation to understand their role in the genesis and evolution of AD and tauopathies.
In general, increased phosphorylation of protein Tau decreases its binding to MT and thereby regulates the normal biological activity of protein Tau related to microtubule spacing, assembly and stability. Obviously, phosphorylation of protein Tau is part of normal physiological regulatory processes and not pathogenic per se [39, 53]. Conversely, in AD and all primary tauopathies, protein Tau becomes more and more phosphorylated with disease progression, to enter a state that is generally referred to as “hyper-phosphorylated.” Nevertheless, no exact lower or upper limits are defined to this connotation, which exposes a major molecular and analytical problem: how many of the vast number of potential O-phosphorylation sites in protein Tau are physiologically relevant? In second order, the question is, are these sites directly pathologically implicated—or merely correlated? We currently address these questions by “timeline” analysis of transgenic mouse brain to define which phosphorylation levels and sites generate or accelerate disease.
While several studies suggest that the functional impact of phosphorylation depends on the specific phosphorylation sites [54–56], others support the notion that overall increased, not site-specific, phosphorylation is sufficient . It is well-known that in development and postnatally, protein Tau is heavily phosphorylated. This “fetal Tau” binds less to MT and helps maintain dynamics of microtubule assembly/disassembly during this period of most active neurite outgrowth, albeit without eliciting tauopathy or neurotoxicity as in ageing brain. Differentiating functional differences between normal Tau in the immature brain and pathological Tau in ageing brain might define phosphorylation of Tau at some specific sites, for example, S199, T231, and S396 in AD brain .
Tau phosphorylation is markedly increased in response to various stressors. Phosphorylation, although to lesser levels than in AD brain, appears to be mobilized by neurons to regulate activity of Tau transiently and reversibly as required. A prime example is hibernation as adaptive process that represents a powerful physiological strategy to withstand periods of limited energy supply. Hibernation is a hypometabolic state with declining body temperature, periodically interrupted by brief spontaneous periods of rewarming to core temperatures, whereby selective expression and control of kinases and phosphatases is an adaptive response for long-term survival . Highly phosphorylated protein Tau readily accumulates and even appears to aggregate in brain of hibernating animals, while most interestingly the entire process is fully reversed when animals arouse, restoring normal temperature and metabolism without harming neurons or networks [60–62].
Other conditions, associated with reduced body temperature and increased Tau phosphorylation are starvation , cold water stress , and anesthesia . Several reports suggest that anesthesia-induced hypothermia increases the risk of AD [66, 67]. Temperature fluctuations affect the relative balance of kinase and phosphatase activity [65, 68]. In a mouse model with incipient neurofibrillary pathology, the pool of free hyperphosphorylated Tau was recruited into Tau aggregates that accumulate over time . Moreover, isoflurane anesthesia in young Tau.P301L transgenic mice provokes brainstem tauopathy and upper airway defects, suggesting similar problems in elderly patients exposed to anesthetics for surgery .
4. Tau Kinases: GSK3 Accepted, Others Explored…
The GSK3 kinases appeal as candidates to modulate Tau phosphorylation for several reasons: (i) they are abundantly expressed in neurons, (ii) their levels and/or enzymatic activity is increased in AD brain [71, 72], and (iii) they can phosphorylate many of the S/T-P sites of protein Tau that are also phosphorylated in AD brain, that is, S199, T231, and S396 [73–75]. Additionally, in our transgenic Tau mouse models, GSK3 greatly increased the severity of tauopathy when expressed in conjunction with mutant Tau.P301L [76, 77], but alleviated the axonopathy when coexpressed with wild-type Tau.4R . Moreover, and surprising for a naturally unfolded protein is the notion that phosphorylation affects the conformation of protein Tau. Monomeric Tau in solution, when phosphorylated at critical sites either upstream or downstream of the MTBD, appeared to adopt a more compact conformation that was proposed to reflect its propensity to aggregate .
The long-standing definition of protein Tau as an axonal protein, and even axonal marker [80, 81], contrasts with the early pathological defects observed in most tauopathies: abnormal delocalization into the somatodendritic compartment where protein Tau becomes even more phosphorylated and subsequently forms the well-known aggregates and NFT. Several hypotheses for the axon-specific location were proposed: axon-specific sorting of mRNA coding for protein Tau or preferential degradation of mRNA and/or protein Tau in dendrites, affected or even steered by selective phosphorylation of protein Tau [82–84]. In the last years, among efforts to clarify these issues a new proposal for a retrograde filtering action dependent on microtubules would allow protein Tau to move into but not out of axons . Moreover, once protein Tau becomes phosphorylated, its microtubular interaction is decreased or disrupted, and phospho-Tau can bypass that barrier. A different mechanism depends on the activation of the PAR-1/MARK kinase to phosphorylate protein Tau downstream of signaling initiated by amyloid , thereby contributing to relocate protein Tau. This would explain its effects on synaptic trafficking, anchoring of glutamate receptors, and interaction with other kinases in disturbing postsynaptic functions [40, 87].
5. The Neurotoxic Species, Known Only as Tau-P*
Intracellular aggregation and deposition of protein Tau as NFT in soma and processes is commonly observed in all tauopathies, including AD. These aggregates, predominantly composed of highly phosphorylated protein Tau, are detergent insoluble and presented either as paired helical filaments (PHF), twisted ribbons, or straight filaments, usually in varying combinations. Although the load of NFT correlates with the severity of cognitive impairment in humans, mouse models for tauopathy demonstrate memory defects to precede NFT-like tauopathy [19, 77, 88, 89]. Moreover, in a conditional model, reversal of Tau expression reversed the cognitive defects even without affecting the Tau deposits [43, 90]. The levels of early multimeric Tau-aggregates that preceded the NFT were found to correlate with memory deficits . These findings corroborate the hypothesis that molecularly unspecified intermediates in the Tau-aggregation cascade, situated between single Tau molecules and large fibrils, are the actual neurotoxic agents. The connotation Tau-P*, as defined previously [19, 92], represents intermediate forms of phosphorylated protein Tau, which remain to be defined molecularly. They are proposed to adopt a transitional conformation state and to be the effective executers of synaptic and eventually neuronal toxicity, if or when they are not directed into formation of the large fibrillar Tau-aggregates that we now consider not or less harmful for neurons. Therefore, decoding the sequence of events that transform soluble or MT-bound Tau into a toxic molecular intermediate that only later becomes an inert aggregate is the key to understand ontogenesis and evolution of any tauopathy. In addition, these studies entertain the idea that therapeutic intervention is possible by acting on the expression, phosphorylation, and aggregation of protein Tau.
The formation of NFT involves sequential steps as studied best with recombinant proteins in vitro and, because cellular models are still lacking, are corroborated by the timeline of events in transgenic mouse brain in vivo . The first step is believed to be the neutralization of the protein Tau-microtubule interaction by phosphorylation by different kinases, increasing the cytoplasmic levels of unbound protein Tau. Moreover, while protein Tau lacks a well-defined structure, the initial phosphorylation promotes an unspecified molecular state that appears favorable for dimerization and aggregation [79, 94]. The adopted presumed β-sheet structure involves the MTBD of protein Tau, whereby eventual disulfide bridging, although not generally accepted, could help shift the equilibrium from soluble monomers to higher-order multimers [95, 96]. Subsequently, further association of β-fibrillar Tau-multimers leads to filaments that deposit as neuropil threads and tangles in the soma.
Biochemical indices for the occurrence of oligomers were interpreted to represent off-pathway aggregates that do not form filaments . Whether or not hyperphosphorylation of protein Tau is an indispensable event for the initial dimerization remains elusive and debated. In vitro studies demonstrated that fibrillar assemblies of protein Tau are not per se phosphorylation dependent  and even that the propensity of protein Tau to form multimers is reduced by phosphorylation particularly of S262 by MARK2/Par1 . Moreover, even the inverse order of events was demonstrated in a mouse model for aggregation of protein Tau, because the incipient aggregation was the actual trigger for subsequent phosphorylation of protein Tau . Consequently, defining the molecular identity of the intermediate Tau species referred to as Tau-P*, a hyperphosphorylated, conformational small aggregate, will be a major step forward on the arduous route to the most appropriate therapeutic target in AD, and in primary tauopathies.
6. Brain-Regional Propagation of Tauopathy
Anatomical patterns of the pathology in human brain suggest, but do not prove, a progressive spreading of tauopathy with progressing cognitive decline . Initial depositions of phosphorylated protein Tau are first observed in the locus coeruleus, one of several subcortical nonthalamic nuclei that has diffuse projection to the cortex. Subsequently, immunochemical defined phosphorylated protein Tau is observed in entorhinal cortex and in its efferent hippocampal and neocortical regions .
This apparent spreading of the tauopathy throughout human brain in a specified regional pattern has been the subject of various hypotheses. Initial evidence for cell-to-cell transfer of protein Tau aggregates came from two studies carried out in cells and in vivo. The first demonstrated that fibrils of protein Tau added to the culture medium were taken up by neuronal cells and caused formation of Tau-aggregates in the cytoplasm . The second reported that in mouse models of tauopathy, intracerebral injection of brain tissue extracts containing Tau-aggregates initiated spreading of intracellular Tau-aggregation from the injection site to other brain areas, although not producing neurodegeneration . These experimental studies still remain controversial and need to be confirmed, eventually to define the route and mechanism whereby cytoplasmic aggregates of protein Tau can become secreted and taken up by neurons, in order to establish the transmittance between neurons as a potential mechanism of spreading of tauopathy in human brain . Most recent data from novel mouse models that express Tau.P301L specifically and only in the entorhinal cortex (ERC) corroborate the hypothesis of cell-to-cell spreading of tauopathy, but leaves the responsible mechanisms open for speculation [105, 106].
7. Mouse Models for Tau Pathology
To understand the impact of Tau phosphorylation and aggregation in synaptic and neuronal degeneration, fully characterized mouse models that exhibit the typical phenotypic features and pathological changes of human tauopathies are needed. Many transgenic mouse models for tauopathy have been developed and characterized over the last decade and were the subject of some recent reviews [19, 88, 107]. Here, we limit the discussion to our mouse models that represent or recapitulate interesting aspects of the pathology of protein Tau in Tau pathologies, including AD.
7.1. Tau.4R Mice
They express full length, wild-type human Tau under control of the mouse Thy-1 gene promoter in the FVB/N genetic background. The advantage of the mouse Thy-1 gene promoter permits neuron-specific expression of the transgene, which begins in the second week postnatally, avoiding interference with development. Tau.4R mice present increased phosphorylation of human protein Tau, however without formation of any Tau-aggregates even at late age . Conversely, Tau.4R mice develop axonopathy, initially consisting first of axonal dilatations or spheroids, evolving into Wallerian degeneration with muscle wasting. The evident motor problems, already present at young age (6 weeks) in homozygous Tau.4R mice, are explained by excessive binding of protein Tau.4R to microtubules. This prevents the normal binding and passage of motor proteins responsible for axonal transport in both directions, resulting in the stochastic accumulation of transported items, from synaptic vesicles to mitochondria over Tau and neurofilament aggregates .
Remarkably, the severe axonopathy and motor problems hardly affect the survival of the Tau.4R mice [89, 108]. Moreover, the pathological phenotype was rescued by coexpression of GSK3β, resulting in bigenic mice that appear largely normal . Molecularly, this is explained by the evident increased phosphorylation by GSK3β of human protein Tau.4R, which displaces it from the microtubules and thereby restores normal axonal transport in both directions. Despite the fact that protein Tau.4R became highly phosphorylated in brain of the Tau.4RxGSK3β bigenic mice, no Tau pathology resulted. Besides demonstrating for the first time in vivo that GSK3β is an effective Tau-kinase, the data also underlined that additional phosphorylation by other kinases is needed to develop tauopathy. A final argument explaining the lack of tauopathy in Tau.4R mice, and by extension in the bigenic Tau.4RxGSK3β mice, was our most recent finding of the strict axonal location of Tau.4R, as opposed to the somatodendritic delocalization of Tau.P301L in transgenic mouse brain [92, 109].
7.2. Tau.P301L Mice
In contrast to Tau.4R mice they exhibit less extensive phosphorylation of mutant protein Tau at younger age, but nevertheless develop into a representative model of tauopathy with neurofibrillary tangles and neuropil threads at older ages. These mice express the well-known human mutant Tau.P301L, the first to be associated with FTDP-17 [22, 23]. Human Tau.P301L is homozygously expressed under control of the same mouse Thy-1 gene promoter and in the same FvB/N genetic background as the Tau.4R mice .
Phosphorylation of Tau.P301L in mouse brain is initially low even up to the age of 7 months at the epitopes defined by Mabs AT8 and AT180, although phosphorylation is detectable with probes AD2 and AT270 . The disease-associated epitope AT100 was even completely absent at young age. In older Tau.P301L mice, phosphorylation of Tau increases leading to reduced affinity of the MT-binding and consequent delocation to soma and dendrites. The local aggregation into tangles and neuropil threads in terminal mice is demonstrated immunohistochemically with Mab AT100 and others, for example, MC1 and PHF1, and biochemically by hyperphosphorylated Tau in the sarkosyl-insoluble fraction (Figure 1) . The development of the tauopathy becomes associated with motor problems, illustrated by clasping and rotarod performance even as early as age 7.5 months, because the hindbrain and particularly specified nuclei in the brainstem, for example, Koelliker-Fuse and raphe, are hit by the tauopathy.
Most recently, we discovered the associated reduction of involuntary control of breathing, resulting in upper-airway defects that cause excessive workload of the diaphragm, leading to impaired ultrasonic vocalization, exhaustion, and asphyxia, most likely associated with dysphagia in old mice. These defects then explain the clinical moribund phenotype of terminal Tau.P301L mice, with dramatic reductions in bodyweight: males drop below 20–18 grams, females below 16 grams. Premature death occurs mainly in the time-window of 8–10 months with the mean around age 9.4 months, not dependent on gender, and with practically no survivors beyond age 12 months. The terminal stage evolves aggressively and takes less than 2-3 weeks after the first signs of motor impairment, whereby the mice rapidly lose body-weight, display a dystonic posture with progressive paralysis of all limbs and associated breathing problems leading to asphyxia, the presumed cause of premature death [11, 89, 110, 111].
Unexpectedly, the cognition of young Tau.P301L mice was markedly better than that of wild-type mice, with ameliorated long-term potentiation in the dentate gyrus and improved cognitive performance in object recognition tests . This was anatomically substantiated by higher levels of mature spines in hippocampus and cortex compared to wild-type mice . Although the spine maturation ratio remained high in hippocampus of adult Tau.P301L mice, the spines regress in length paralleling the impaired cognition, the increased phosphorylation and relocation of protein Tau.P301L from axons to soma and neuritic processes [109, 112].
Tau.P301L mice do not suffer any amyloid pathology and do not stand as a model for AD pathology, but these monogenic mice are an excellent model to study the impact of hyperphosphorylation and aggregation of protein Tau in different Tau pathologies. The progressive impairment that we documented in the Tau.P301L mice, starting from defective learning and memory in adults to problems at later age with breathing and vocalization, swallowing, movement, and motor defects, Tau phosphorylation, and aggregation into tangles, all correspond with features known from human tauopathies and neurodegenerative diseases. Needless to state that the effect of drugs or disease modifying treatments that target the pathological Tau, or its downstream partners or sequellae, can be evaluated in the monogenic Tau.P301L mice [19, 113].
7.3. biAT and biGT Mice
To define the relations and synergism between amyloid and Tau pathology in AD, and of the role of the GSK3 kinases, double transgenic mice were developed by combining homozygous Tau.P301L mice with either heterozygous human GSK3β.[S9A] mice or APP.V717I mice [77, 78, 114, 115], resulting, respectively, in GSK3βxTau.P301L (biGT) and APP.V717IxTau.P301L (biAT) bigenic mice. In both strains, the Tau pathology is aggravated with ageing by progressively increasing phosphorylation of Tau.P301L at typical pathological and conformational epitopes, resulting in the formation of highly fibrillary tangles and threads in cortex and hippocampus . Conversely, in the brainstem of biGT mice the Tau pathology was significantly reduced relative to that in the parental Tau.P301L mice, which correlates with the markedly prolonged survival of the biGT mice compared to Tau.P301L mice: IC50 of 13 months versus 9.3 months, respectively.
Originally, we observed and described prolonged survival of the biAT mice, which was explained, by the increased activation of both GSK3 isozymes, that is, increased tyrosine phosphorylation, apparently driven by the high amyloid burden, as it was observed in the parental monogenic APP.V717I mice . The subsequent in-depth further characterization of the biAT mice revealed a more complex pattern of mortality, which will be reported in detail elsewhere . In brief, young biAT mice are prone to spontaneous or evoked epileptic seizures that cause a significant premature death in the tile-window of 1–6 months. Mortality is thereby evident at younger age and more frequent than in the parental APP.V717I mice .
Thereafter, mortality subsides, with a sizable fraction of biAT mice, particularly females surviving longer than the parental Tau.P301L mice. Of note, the female survivors develop, more severely than males, the typical combined AD-related pathology in relevant brain regions, that is, hippocampus, neocortex, entorhinal cortex, piriform cortex, and amygdala [77, 115]. In the forebrain of surviving biAT mice, the amyloid pathology with intracellular vesicular amyloid, extracellular diffuse and senile plaques, and vascular amyloid sets in at age from 10 to 12 months, preceding the Tau pathology. Of note, intracellular vesicular amyloid accumulation is already evident at young age (4–6 months) and is accompanied by increased phosphorylation of endogenous mouse Tau and of human Tau.P301L at the AT8 site. The timing remarkably coincides with the activation of the GSK3 kinases by intramolecular tyrosine phosphorylation and with the hippocampus-dependent cognitive deficits of APP.V717I and biAT mice. Cognition is already impaired at young adult age (age 4–6 months), well before the onset of amyloid deposition or Tau pathology, sensu stricto. Young adult biAT mice are severely impaired even in less demanding tests, that is, novel object recognition, passive inhibitory avoidance, and conditioned taste aversion .
Similar to humans suffering progressive senile types of dementia, ageing severely impacts the clinical phenotype of the bigenic mice, particularly of the biAT mice with progressive reduction in body weight, loss of ambulation, and reduced fur condition following the more early cognitive and behavioral impairments. The comparative evolution in both bigenic strains with ageing point to comparative underlying mechanisms, adding support to the hypothesis that amyloid triggers the tauopathy by increasing GSK3 activity [77, 118, 119].
8. Hypothesis: Tau, Phospho-Tau, Tau-P*, Oligomers, Fibrils, and Tangles
“…a stage, and all the…merely players” W. Shakespeare 1598.
The molecular characterization of protein species intermediate between the monomers prepared by biochemists and the large fibrils observed postmortem by the pathologists is a hot topic in current neuroscience research and for many proteins that are proven or surmised to be implicated in neurodegenerative disorder [15, 120–123]. Probably, amyloid is the most advanced in this respect, although no single intermediate Aβ-oligomer is yet accepted as the only or even major toxic species. Relying on thermodynamics and mass-action laws, one can even predict that a single species will never be identified as the proven cause of all the distress in AD brain over a period of 20 years, or more.
Pathological and experimental evidence increasingly questions the direct link between intraneuronal accumulation of Tau-aggregates and the neuronal degeneration observed in the later phases of dementia.
Many neurons that accumulate NFT in aged human brain and in transgenic mouse brain are not marked by characteristic morphological signs of cellular death. Conversely, many neurons that do bear such markers do not appear to have a significant load of high-order Tau filaments [44, 124].
Therefore, both tangle formation and neuron loss should be considered as dissociated processes, at least in time, but likely also in actual underlying mechanisms (Figure 2). Direct assessment of the relation of tangles and neuronal function by electrophysiology of individual neurons ex vivo, concomitant with structural analysis of dendritic branching and spines, did not correlate with NFT bearing . Similarly, the findings in mammalian models was also observed in invertebrate Tau models [126, 127]. The justified conclusion must be that other, less aggregated or even soluble forms of protein Tau are responsible for neuronal dysfunction and by extension for failing synaptic plasticity and cognition. More and more, NFTs are regarded to function as the intraneuronal sink for excess phosphorylated protein Tau that was released from the axonal microtubules and after delocalization and extra phosphorylation is unable to regain its normal physiological position and function. By forming large fibrillar aggregates, neurons are protected from toxic effects of soluble, smaller aggregates [128, 129], a mechanism that was even proposed as a potential therapeutic approach . Obviously, the cytoplasmic sink is limited in capacity and this protective measure cannot but be limited in time, eventually resulting in the damage and death of the neuron, exemplified by the presence of ghost tangles in the later stages of tauopathy .
Tau species responsible for cognitive dysfunction were tentatively identified as multimers of apparent Mr 170 kDa, present in FTD and AD brain, and correlating with memory index and motor deficits in tauopathy models . Furthermore, Tau oligomers prepared with Aβ oligomers as initial seed invoked memory impairment and synaptic and mitochondrial dysfunction in wild-type mice . Invertebrate transgenic models, for example, drosophila that express wild-type or mutant Tau isoforms also concluded to soluble cytosolic Tau species as accountable for toxicity [48, 132].
Conversely, our own experiments with AAV-based vectors in wild-type mice revealed early damage mainly to dendrites by human wild-type and mutant Tau alike, accompanied by extensive phosphorylation and smaller Tau-aggregates of Tau, but without formation of larger fibrils [47, 133]. The situation led us to postulate that a phosphorylated intermediate, most likely a dimer or small aggregate that we termed Tau-P*, is responsible for cognitive dysfunction by synaptic toxicity . Our hypothesis hinges on the concept that the production of Tau-P* molecules constitutes for the neuron the tipping-point of whether or not to form the protective large aggregates. If for some reason, this is not possible, the accumulation of Tau-P* molecules will damage the neuron and impair synaptic function and plasticity, causing cognitive dysfunction (Figure 2).
This concept incorporates different signaling mechanism hinging on GSK3, and without abandoning the amyloid hypothesis. In the light of in vivo observations in transgenic mice, discussed in the foregoing sections, we maintain the GSK3 kinases center-stage as important link between the two pathologies in AD, reconciling the amyloid and Tau doctrines [77, 92, 119]. Activation of both GSK3 kinases by aberrant Aβ production and/or APP processing  is not the primary cause of the disease, but a major link to turn on the phosphorylation-cascade of protein Tau and the formation of Tau-P* intermediates. We realize that one kinase cannot suit all the known phosphorylation sites on protein Tau, while also the transformation of Tau-P* to NFT must depend on unknown factors (Figure 2). Moreover, the relation to the early and late cognitive impairment must depend on a host of as yet unknown molecular factors, termed X-factors before [19, 113] that must be held liable for the clinical symptoms in AD. Different factors in different individuals are expected to help explain the variable onset and evolution, as well as the variable cognitive and behavioral symptoms despite similar, although also variable brain pathology.
The authors sincerely thank many collaborators and scientists for technical assistance, advice, materials, and scientific and moral support. The investigations were made possible by funding and support from the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO-Vlaanderen), the Instituut voor Wetenschap en Techniek (IWT), the EEC-6th and 7th Framework Programs (neuroGSK3), the Rooms-fund, the KULeuven-Research Fund (BOF), and KULeuven-Research & Development.
- K. A. Jellinger, “Alzheimer 100—highlights in the history of Alzheimer research,” Journal of Neural Transmission, vol. 113, no. 11, pp. 1603–1623, 2006.
- S. W. Scheff, S. T. DeKosky, and D. A. Price, “Quantitative assessment of cortical synaptic density in Alzheimer's disease,” Neurobiology of Aging, vol. 11, no. 1, pp. 29–37, 1990.
- S. W. Scheff and D. A. Price, “Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies,” Neurobiology of Aging, vol. 24, no. 8, pp. 1029–1046, 2003.
- S. W. Scheff and D. A. Price, “Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus,” Journal of Alzheimer's Disease, vol. 9, no. 3, pp. 101–115, 2006.
- R. D. Terry, E. Masliah, D. P. Salmon et al., “Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment,” Annals of Neurology, vol. 30, no. 4, pp. 572–580, 1991.
- J. Hardy and D. Allsop, “Amyloid deposition as the central event in the aetiology of Alzheimer's disease,” Trends in Pharmacological Sciences, vol. 12, no. 10, pp. 383–388, 1991.
- J. A. Hardy and G. A. Higgins, “Alzheimer's disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992.
- J. Hardy, “Alzheimer's disease: the amyloid cascade hypothesis—an update and reappraisal,” Journal of Alzheimer's Disease, vol. 9, no. 3, pp. 151–153, 2006.
- C. Haass, M. G. Schlossmacher, A. Y. Hung et al., “Amyloid β-peptide is produced by cultured cells during normal metabolism,” Nature, vol. 359, no. 6393, pp. 322–325, 1992.
- T. Vandebroek, T. Vanhelmont, D. Terwel et al., “Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast,” Biochemistry, vol. 44, no. 34, pp. 11466–11475, 2005.
- C. Menuet, P. Borghgraef, V. Matarazzo, et al., “Raphe tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease,” Respiratory Physiology & Neurobiology, vol. 178, no. 2, pp. 290–303, 2011.
- R. E. Tanzi and L. Bertram, “Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective,” Cell, vol. 120, no. 4, pp. 545–555, 2005.
- H. A. Archer, P. Edison, D. J. Brooks et al., “Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study,” Annals of Neurology, vol. 60, no. 1, pp. 145–147, 2006.
- Y. Li, J. O. Rinne, L. Mosconi et al., “Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2169–2181, 2008.
- M. Jin, N. Shepardson, T. Yang, G. Chen, D. Walsh, and D. J. Selkoe, “Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5819–5824, 2011.
- C. Duyckaerts, B. Delatour, and M. C. Potier, “Classification and basic pathology of Alzheimer disease,” Acta Neuropathologica, vol. 118, no. 1, pp. 5–36, 2009.
- P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte, and B. T. Hyman, “Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease,” Neurology, vol. 42, no. 3 I, pp. 631–639, 1992.
- R. B. Maccioni, M. Lavados, M. Guillon, et al., “Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects,” Neurobiology of Aging, vol. 27, no. 2, pp. 237–244, 2006.
- T. Jaworski, I. Dewachter, C. M. Seymour et al., “Alzheimer's disease: old problem, new views from transgenic and viral models,” Biochimica et Biophysica Acta, vol. 1802, no. 10, pp. 808–818, 2010.
- A. Harada, K. Oguchi, S. Okabe et al., “Altered microtubule organization in small-calibre axons of mice lacking tau protein,” Nature, vol. 369, no. 6480, pp. 488–491, 1994.
- L. N. Clark, P. Poorkaj, Z. Wszolek et al., “Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 13103–13107, 1998.
- M. Goedert, R. A. Crowther, and M. G. Spillantini, “Tau mutations cause frontotemporal dementias,” Neuron, vol. 21, no. 5, pp. 955–958, 1998.
- M. Hong, M. Hong, V. Zhukareva et al., “Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17,” Science, vol. 282, no. 5395, pp. 1914–1917, 1998.
- M. Hutton, C. L. Lendon, P. Rizzu et al., “Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17,” Nature, vol. 393, no. 6686, pp. 702–705, 1998.
- J. Z. Wang and F. Liu, “Microtubule-associated protein tau in development, degeneration and protection of neurons,” Progress in Neurobiology, vol. 85, no. 2, pp. 148–175, 2008.
- T. F. Gendron and L. Petrucelli, “The role of tau in neurodegeneration,” Molecular Neurodegeneration, vol. 4, no. 1, article 13, 2009.
- J. van Swieten and M. G. Spillantini, “Hereditary frontotemporal dementia caused by tau gene mutations,” Brain Pathology, vol. 17, no. 1, pp. 63–73, 2007.
- J. Zhou, Q. Yu, and T. Zou, “Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies,” BMC Neuroscience, vol. 9, supplement 2, article S10, 2008.
- M. S. Wolfe, “Tau mutations in neurodegenerative diseases,” The Journal of Biological Chemistry, vol. 284, no. 10, pp. 6021–6025, 2009.
- D. G. Drubin, D. Caput, and M. W. Kirschner, “Studies on the expression of the microtubule-associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes,” Journal of Cell Biology, vol. 98, no. 3, pp. 1090–1097, 1984.
- L. I. Binder, A. Frankfurter, and L. I. Rebhun, “The distribution of tau in the mammalian central nervous system,” Journal of Cell Biology, vol. 101, no. 4, pp. 1371–1378, 1985.
- L. Buee and A. Delacourte, “Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease,” Brain Pathology, vol. 9, no. 4, pp. 681–693, 1999.
- M. G. Spillantini and M. Goedert, “Tau protein pathology in neurodegenerative diseases,” Trends in Neurosciences, vol. 21, no. 10, pp. 428–433, 1998.
- M. G. Spillantini, T. D. Bird, and B. Ghetti, “Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies,” Brain Pathology, vol. 8, no. 2, pp. 387–402, 1998.
- A. M. Pittman, H. C. Fung, and R. de Silva, “Untangling the tau gene association with neurodegenerative disorders,” Human Molecular Genetics, vol. 15, no. 2, pp. R188–R195, 2006.
- B. Trinczek, J. Biernat, K. Baumann, E. M. Mandelkow, and E. Mandelkow, “Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules,” Molecular Biology of the Cell, vol. 6, no. 12, pp. 1887–1902, 1995.
- G. B. Witman, D. W. Cleveland, M. D. Weingarten, and M. W. Kirschner, “Tubulin requires tau for growth into microtubule initiating sites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 73, no. 11, pp. 4070–4074, 1976.
- S. Kar, J. Fan, M. J. Smith, M. Goedert, and L. A. Amos, “Repeat motifs of tau bind to the insides of microtubules in the absence of taxol,” The EMBO Journal, vol. 22, no. 1, pp. 70–77, 2003.
- R. Dixit, J. L. Ross, Y. E. Goldman, and E. L. F. Holzbaur, “Differential regulation of dynein and kinesin motor proteins by tau,” Science, vol. 319, no. 5866, pp. 1086–1089, 2008.
- L. M. Ittner, Y. D. Ke, F. Delerue et al., “Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models,” Cell, vol. 142, no. 3, pp. 387–397, 2010.
- C. J. Leugers and G. Lee, “Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding,” The Journal of Biological Chemistry, vol. 285, no. 25, pp. 19125–19134, 2010.
- M. Morris, S. Maeda, K. Vossel, and L. Mucke, “The many faces of tau,” Neuron, vol. 70, no. 3, pp. 410–426, 2011.
- K. Santacruz, J. Lewis, T. Spires et al., “Tau suppression in a neurodegenerative mouse model improves memory function,” Science, vol. 309, no. 5733, pp. 476–481, 2005.
- C. Andorfer, C. M. Acker, Y. Kress, P. R. Hof, K. Duff, and P. Davies, “Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms,” Journal of Neuroscience, vol. 25, no. 22, pp. 5446–5454, 2005.
- T. Gomez-Isla, R. Hollister, H. West et al., “Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease,” Annals of Neurology, vol. 41, no. 1, pp. 17–24, 1997.
- E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., “Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model,” Science, vol. 316, no. 5825, pp. 750–754, 2007.
- T. Jaworski, I. Dewachter, B. Lechat et al., “AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice,” PLoS One, vol. 4, no. 10, Article ID e7280, 2009.
- S. Feuillette, L. Miguel, T. Frebourg, D. Campion, and M. Lecourtois, “Drosophila models of human tauopathies indicate that tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein,” Journal of Neurochemistry, vol. 113, no. 4, pp. 895–903, 2010.
- V. Dorval and P. E. Fraser, “Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein,” The Journal of Biological Chemistry, vol. 281, no. 15, pp. 9919–9924, 2006.
- S. W. Min, S. H. Cho, Y. Zhou et al., “Acetylation of tau inhibits its degradation and contributes to tauopathy,” Neuron, vol. 67, no. 6, pp. 953–966, 2010.
- M. D. Ledesma, M. Perez, C. Colaco, and J. Avila, “Tau glycation is involved in aggregation of the protein but not in the formation of filaments,” Cellular and Molecular Biology, vol. 44, no. 7, pp. 1111–1116, 1998.
- M. Takahashi, Y. Tsujioka, T. Yamada et al., “Glycosylation of microtubule-associated protein tau in Alzheimer's disease brain,” Acta Neuropathologica, vol. 97, no. 6, pp. 635–641, 1999.
- C. Conde and A. Caceres, “Microtubule assembly, organization and dynamics in axons and dendrites,” Nature Reviews Neuroscience, vol. 10, no. 5, pp. 319–332, 2009.
- J. Gotz, F. Chen, J. van Dorpe, and R. M. Nitsch, “Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ 42 fibrils,” Science, vol. 293, no. 5534, pp. 1491–1495, 2001.
- A. Ferrari, F. Hoerndli, T. Baechi, R. M. Nitsch, and J. Gotz, “β-Amyloid induces paired helical filament-like tau filaments in tissue culture,” The Journal of Biological Chemistry, vol. 278, no. 41, pp. 40162–40168, 2003.
- I. Kelleher, C. Garwood, D. P. Hanger, B. H. Anderton, and W. Noble, “Kinase activities increase during the development of tauopathy in htau mice,” Journal of Neurochemistry, vol. 103, no. 6, pp. 2256–2267, 2007.
- M. L. Steinhilb, D. Dias-Santagata, T. A. Fulga, D. L. Felch, and M. B. Feany, “Tau phosphorylation sites work in concert to promote neurotoxicity in vivo,” Molecular Biology of the Cell, vol. 18, no. 12, pp. 5060–5068, 2007.
- Y. Yu, X. Run, Z. Liang et al., “Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases,” Journal of Neurochemistry, vol. 108, no. 6, pp. 1480–1494, 2009.
- K. B. Storey, “Mammalian hibernation: transcriptional and translational controls,” Advances in Experimental Medicine and Biology, vol. 543, pp. 21–38, 2003.
- J. T. Stieler, T. Bullmann, F. Kohl, et al., “The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation,” PLoS One, vol. 6, no. 1, Article ID e14530, 2011.
- W. Hartig, J. Stieler, A. S. Boerema et al., “Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons—implications for Alzheimer's disease,” European Journal of Neuroscience, vol. 25, no. 1, pp. 69–80, 2007.
- T. Arendt, J. Stieler, A. M. Strijkstra et al., “Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals,” Journal of Neuroscience, vol. 23, no. 18, pp. 6972–6981, 2003.
- M. Yanagisawa, E. Planel, K. Ishiguro, and S. C. Fujita, “Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease,” The FEBS Letters, vol. 461, no. 3, pp. 329–333, 1999.
- Y. Okawa, K. Ishiguro, and S. C. Fujita, “Stress-induced hyperphosphorylation of tau in the mouse brain,” The FEBS Letters, vol. 535, no. 1–3, pp. 183–189, 2003.
- E. Planel, K. E. G. Richter, C. E. Nolan et al., “Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia,” Journal of Neuroscience, vol. 27, no. 12, pp. 3090–3097, 2007.
- N. Bohnen, M. A. Warner, E. Kokmen, and L. T. Kurland, “Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease,” International Journal of Neuroscience, vol. 77, no. 3-4, pp. 181–185, 1994.
- I. Bone and M. Rosen, “Alzheimer's disease and anaesthesia,” Anaesthesia, vol. 55, no. 6, pp. 592–593, 2000.
- E. Planel, T. Miyasaka, T. Launey et al., “Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease,” Journal of Neuroscience, vol. 24, no. 10, pp. 2401–2411, 2004.
- E. Planel, A. Bretteville, L. Liu et al., “Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia,” The FASEB Journal, vol. 23, no. 8, pp. 2595–2604, 2009.
- C. Menuet, P. Borghgraef, N. Voituron, et al., “Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: possible implication for neurodegenerative diseases,” Neurobiology of Disease, vol. 46, no. 1, pp. 234–243, 2012.
- K. Leroy, Z. Yilmaz, and J. P. Brion, “Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration,” Neuropathology and Applied Neurobiology, vol. 33, no. 1, pp. 43–55, 2007.
- A. Takashima, “GSK-3 is essential in the pathogenesis of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 9, no. 3, pp. 309–317, 2006.
- K. Ishiguro, A. Shiratsuchi, S. Sato et al., “Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filaments,” The FEBS Letters, vol. 325, no. 3, pp. 167–172, 1993.
- C. A. Rankin, Q. Sun, and T. C. Gamblin, “Pre-assembled tau filaments phosphorylated by GSK-3b form large tangle-like structures,” Neurobiology of Disease, vol. 31, no. 3, pp. 368–377, 2008.
- J. S. Song and S. D. Yang, “Tau protein kinase I/GSK-3β/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain,” Journal of Protein Chemistry, vol. 14, no. 2, pp. 95–105, 1995.
- T. Engel, J. J. Lucas, P. Gomez-Ramos, M. A. Moran, J. Avila, and F. Hernandez, “Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration,” Neurobiology of Aging, vol. 27, no. 9, pp. 1258–1268, 2006.
- D. Terwel, D. Muyllaert, I. Dewachter et al., “Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice,” American Journal of Pathology, vol. 172, no. 3, pp. 786–798, 2008.
- K. Spittaels, C. van den Haute, J. van Dorpe et al., “Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice,” The Journal of Biological Chemistry, vol. 275, no. 52, pp. 41340–41349, 2000.
- S. Jeganathan, A. Hascher, S. Chinnathambi, J. Biernat, E. M. Mandelkow, and E. Mandelkow, “Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation,” The Journal of Biological Chemistry, vol. 283, no. 46, pp. 32066–32076, 2008.
- S. C. Papasozomenos and L. I. Binder, “Phosphorylation determines two distinct species of tau in the central nervous system,” Cell motility and the cytoskeleton, vol. 8, no. 3, pp. 210–226, 1987.
- C. G. Dotti, G. A. Banker, and L. I. Binder, “The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture,” Neuroscience, vol. 23, no. 1, pp. 121–130, 1987.
- N. Hirokawa, T. Funakoshi, R. Sato-Harada, and Y. Kanai, “Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons,” Journal of Cell Biology, vol. 132, no. 4, pp. 667–679, 1996.
- S. Aronov, G. Aranda, L. Behar, and I. Ginzburg, “Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal,” Journal of Neuroscience, vol. 21, no. 17, pp. 6577–6587, 2001.
- K. S. Kosik and A. M. Krichevsky, “The message and the messenger: delivering RNA in neurons,” Science's STKE, vol. 2002, no. 126, article e16, 2002.
- X. Li, Y. Kumar, H. Zempel, E. M. Mandelkow, J. Biernat, and E. Mandelkow, “Novel diffusion barrier for axonal retention of tau in neurons and its failure in neurodegeneration,” The EMBO Journal, vol. 30, no. 23, pp. 4825–4837, 2011.
- W. Yu, J. Polepalli, D. Wagh, J. Rajadas, R. Malenka, and B. Lu, “A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines,” Human Molecular Genetics, vol. 21, no. 6, pp. 1384–1390, 2011.
- B. R. Hoover, M. N. Reed, J. Su et al., “Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration,” Neuron, vol. 68, no. 6, pp. 1067–1081, 2010.
- J. Gotz, A. Gladbach, L. Pennanen et al., “Animal models reveal role for tau phosphorylation in human disease,” Biochimica et Biophysica Acta, vol. 1802, no. 10, pp. 860–871, 2010.
- D. Terwel, R. Lasrado, J. Snauwaert et al., “Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice,” The Journal of Biological Chemistry, vol. 280, no. 5, pp. 3963–3973, 2005.
- T. L. Spires, J. D. Orne, K. SantaCruz et al., “Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy,” American Journal of Pathology, vol. 168, no. 5, pp. 1598–1607, 2006.
- Z. Berger, H. Roder, A. Hanna et al., “Accumulation of pathological tau species and memory loss in a conditional model of tauopathy,” Journal of Neuroscience, vol. 27, no. 14, pp. 3650–3662, 2007.
- A. Kremer, J. V. Louis, T. Jaworski, and F. van Leuven, “GSK3 and Alzheimer's disease: facts and fiction...,” Frontiers in Molecular Neuroscience, vol. 4, article 17, 2011.
- J. Kuret, C. N. Chirita, E. E. Congdon et al., “Pathways of tau fibrillization,” Biochimica et Biophysica Acta, vol. 1739, no. 2, pp. 167–178, 2005.
- S. Barghorn and E. Mandelkow, “Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments,” Biochemistry, vol. 41, no. 50, pp. 14885–14896, 2002.
- N. Sahara, S. Maeda, M. Murayama et al., “Assembly of two distinct dimers and higher-order oligomers from full-length tau,” European Journal of Neuroscience, vol. 25, no. 10, pp. 3020–3029, 2007.
- A. Watanabe, W. K. Hong, N. Dohmae, K. Takio, M. Morishima-Kawashima, and Y. Ihara, “Molecular aging of tau: disulfide-independent aggregation and non-enzymatic degradation in vitro and in vivo,” Journal of Neurochemistry, vol. 90, no. 6, pp. 1302–1311, 2004.
- K. R. Patterson, C. Remmers, Y. Fu et al., “Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease,” The Journal of Biological Chemistry, vol. 286, no. 26, pp. 23063–23076, 2011.
- A. Schneider, J. Biernat, M. von Bergen, E. Mandelkow, and E. M. Mandelkow, “Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments,” Biochemistry, vol. 38, no. 12, pp. 3549–3558, 1999.
- A. Sydow, A. van der Jeugd, F. Zheng et al., “Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant,” Journal of Neuroscience, vol. 31, no. 7, pp. 2511–2525, 2011.
- H. Braak and E. Braak, “Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections,” Brain Pathology, vol. 1, no. 3, pp. 213–216, 1991.
- H. Braak and K. Del Tredici, “The pathological process underlying Alzheimer's disease in individuals under thirty,” Acta Neuropathologica, vol. 121, no. 2, pp. 171–181, 2011.
- B. Frost, R. L. Jacks, and M. I. Diamond, “Propagation of tau misfolding from the outside to the inside of a cell,” The Journal of Biological Chemistry, vol. 284, no. 19, pp. 12845–12852, 2009.
- F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission and spreading of tauopathy in transgenic mouse brain,” Nature Cell Biology, vol. 11, no. 7, pp. 909–913, 2009.
- L. M. Ittner and J. Gotz, “Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease,” Nature Reviews Neuroscience, vol. 12, no. 2, pp. 67–72, 2011.
- A. de Calignon, M. Polydoro, M. Suarez-Calvet, et al., “Propagation of tau pathology in a model of early Alzheimer's disease,” Neuron, vol. 73, no. 4, pp. 685–697, 2012.
- L. Liu, V. Drouet, J. W. Wu, et al., “Trans-synaptic spread of tau pathology in vivo,” PLoS One, vol. 7, no. 2, Article ID e31302, 2012.
- C. Duyckaerts, M. C. Potier, and B. Delatour, “Alzheimer disease models and human neuropathology: similarities and differences,” Acta Neuropathologica, vol. 115, no. 1, pp. 5–38, 2008.
- K. Spittaels, C. van den Haute, J. van Dorpe et al., “Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein,” American Journal of Pathology, vol. 155, no. 6, pp. 2153–2165, 1999.
- A. Kremer, H. Maurin, D. Demedts, H. Devijver, P. Borghgraef, and F. van Leuven, “Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice,” Journal of Neuroscience, vol. 31, no. 49, pp. 18036–18047, 2011.
- M. Dutschmann, C. Menuet, G. M. Stettner et al., “Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei,” Journal of Neuroscience, vol. 30, no. 5, pp. 1810–1821, 2010.
- C. Menuet, Y. Cazals, C. Gestreau, et al., “Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders,” PLoS One, vol. 6, no. 10, Article ID e25770, 2011.
- K. Boekhoorn, D. Terwel, B. Biemans et al., “Improved long-term potentiation and memory in young Tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy,” Journal of Neuroscience, vol. 26, no. 13, pp. 3514–3523, 2006.
- T. Jaworski, S. Kugler, and F. van Leuven, “Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease,” International Journal of Alzheimer's Disease, vol. 2010, Article ID 573138, 10 pages, 2010.
- K. Spittaels, C. van den Haute, J. van Dorpe et al., “Neonatal neuronal overexpression of glycogen synthase kinase-3β reduces brain size in transgenic mice,” Neuroscience, vol. 113, no. 4, pp. 797–808, 2002.
- D. Moechars, I. Dewachter, K. Lorent et al., “Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain,” The Journal of Biological Chemistry, vol. 274, no. 10, pp. 6483–6492, 1999.
- A. Kremer, H. Maurin, P. Borghgraef, et al., “Time-line of clinical and pathological defects of mice with amyloid and tau pathology: relations to dendritic spines and location of amyloid and protein tau,” in preparation, 2012.
- D. Moechars, K. Lorent, and F. van Leuven, “Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis,” Neuroscience, vol. 91, no. 3, pp. 819–830, 1999.
- D. Muyllaert, A. Kremer, T. Jaworski et al., “Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?” Genes, Brain and Behavior, vol. 7, no. 1, pp. 57–66, 2008.
- D. Muyllaert, D. Terwel, P. Borghgraef, H. Devijver, I. Dewachter, and F. van Leuven, “Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology,” Reviews of Neurology, vol. 162, no. 10, pp. 903–907, 2006.
- K. A. Conway, S. J. Lee, J. C. Rochet, T. T. Ding, R. E. Williamson, and P. T. Lansbury Jr., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 571–576, 2000.
- D. B. Freir, R. Fedriani, D. Scully, et al., “Aβ oligomers inhibit synapse remodelling necessary for memory consolidation,” Neurobiology of Aging, vol. 32, no. 12, pp. 2211–2218, 2011.
- J. Legleiter, E. Mitchell, G. P. Lotz et al., “Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo,” The Journal of Biological Chemistry, vol. 285, no. 19, pp. 14777–14790, 2010.
- V. Novitskaya, O. V. Bocharova, I. Bronstein, and I. V. Baskakov, “Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons,” The Journal of Biological Chemistry, vol. 281, no. 19, pp. 13828–13836, 2006.
- J. J. Kril, S. Patel, A. J. Harding, and G. M. Halliday, “Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation,” Acta Neuropathologica, vol. 103, no. 4, pp. 370–376, 2002.
- A. B. Rocher, J. L. Crimins, J. M. Amatrudo et al., “Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs,” Experimental Neurology, vol. 223, no. 2, pp. 385–393, 2010.
- J. Wentzell and D. Kretzschmar, “Alzheimer's disease and tauopathy studies in flies and worms,” Neurobiology of Disease, vol. 40, no. 1, pp. 21–28, 2010.
- C. M. Cowan, M. A. Sealey, S. Quraishe, et al., “Modelling tauopathies in Drosophila: insights from the fruit fly,” International Journal of Alzheimer's Disease, vol. 2011, Article ID 598157, 16 pages, 2011.
- E. E. Congdon and K. E. Duff, “Is tau aggregation toxic or protective?” Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 453–457, 2008.
- A. D. C. Alonso, B. Li, I. Grundke-Iqbal, and K. Iqbal, “Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 23, pp. 8864–8869, 2006.
- R. A. Bodner, T. F. Outeiro, S. Altmann et al., “Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 11, pp. 4246–4251, 2006.
- C. A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, A. L. Clos, G. R. Jackson, and R. Kayed, “Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice,” Molecular Neurodegeneration, vol. 6, no. 1, article 39, 2011.
- K. Papanikolopoulou, S. Kosmidis, S. Grammenoudi, and E. M. C. Skoulakis, “Phosphorylation differentiates tau-dependent neuronal toxicity and dysfunction,” Biochemical Society Transactions, vol. 38, no. 4, pp. 981–987, 2010.
- T. Jaworski, B. Lechat, D. Demedts, et al., “Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration,” American Journal of Pathology, vol. 179, no. 4, pp. 2001–2015, 2011.
- T. Jaworski, I. Dewachter, B. Lechat, et al., “GSK-3α/β kinases and amyloid production in vivo,” Nature, vol. 480, no. 7376, pp. E4–E5, 2011.